叔丁基4-溴-2-氧代-2,5-二氢-1H-吡咯-1-甲酸叔丁酯 | 947407-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 中文名称: 叔丁基4-溴-2-氧代-2,5-二氢-1H-吡咯-1-甲酸叔丁酯
• 英文名称: tert-butyl 4-bromo-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate
• 英文别名: tert-butyl 3-bromo-5-oxo-2H-pyrrole-1-carboxylate
• CAS: 947407-87-6
• 化学式: C₉H₁₂BrNO₃
• 分子量: 262.103
• InChiKey: BPZPSQDKVBXRRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H317

反应信息

• 作为反应物：
  描述：

  叔丁基4-溴-2-氧代-2,5-二氢-1H-吡咯-1-甲酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-bromo-3-pyrrolin-2-one
  参考文献：
  名称：

  Synthesis of 4-Substituted 1,5-Dihydropyrrol-2-ones and 5,6-Dihydro-1H-pyridin-2-ones by Negishi Cross-Coupling Reactions: Short Access to the Antidepressant (±)-Rolipram

  摘要：

  通过易得的溴化物3和6与各种官能化锌试剂的钯催化的根岸偶联反应,建立了一种合成目标化合物的直接方法(产率71-97%)。

  DOI：

  10.1055/s-2007-982553
• 作为产物：
  描述：

  2,5-二氢-4-羟基-2-氧代-1H-吡咯-1-甲酸叔丁酯 在 草酰溴 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.25h， 以50%的产率得到叔丁基4-溴-2-氧代-2,5-二氢-1H-吡咯-1-甲酸叔丁酯
  参考文献：
  名称：

  1,5-二氢吡咯-2-酮和5,6-二氢-1 H-吡啶-2-酮与C，N和O连接的烯基侧链的制备及分子内[2 + 2]-光环加成4位置

  摘要：

  1,5-二氢吡咯-2-酮2，6，9，和11（从甲基tetramates制备1A - Ç），Ñ -Boc保护的特特拉姆酸（3），或ñ -Boc保护的特特拉姆酸溴化物（7）以短的反应顺序和非常好的总产率。同源5,6-二氢-1- ħ -吡啶-2-酮16，18，20，21，23，和27分别沿着从哌啶-2,4-二酮起始类似途径制备（19），或者从它的ñ -叔丁基衍生物15。[2 + 2]-光环加成反应的最佳条件包括使用二氯甲烷作为溶剂和用汞低压灯（λ= 254 nm）照射。当在环境温度下施加这些条件下，相应的分子内光环产品28 - 37以良好的收率（52-79％）中，用非对映选择性完美得到。通过NMR光谱阐明了产物的组成和构型。对于O系衬底2a和20，观察到光环加成率随温度强烈降低。的效果不太明显了N-和C-拴基板6，9，23，和27。使用手性络合剂实现对映选择性反应似乎是可行的。然而，络合剂（-）-

  DOI：

  10.1021/jo7027129

文献信息

• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089830A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，其为一种或多种突变IDH酶的抑制剂；其中A为-C(R1)=或-N=；X从以下组中选择：(II-i)和(II-ii)。本发明还涉及所述三环化合物在潜在治疗或预防涉及一种或多种突变IDH酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES COMME INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089833A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), (II-ii), (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，这些化合物是一种或多种突变IDH酶的抑制剂：(I)；其中A为-C(R1)=或-N=；X选自以下组中的一种：(II-i)、(II-ii)、(II-iii)和(II-iv)。本发明还涉及所述三环化合物在潜在治疗或预防涉及一种或多种突变IDH酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• Tricyclic compounds as inhibitors of mutant IDH enzymes
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10086000B2

  公开（公告）日：2018-10-02

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is —C(R1)= or —N═; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，它是一种或多种突变IDH酶的抑制剂：(I)；其中A是-C(R1)＝或-N═；X选自由(II-i)、(II-ii)、(I)(II-iii)和(II-iv)组成的组。本发明还涉及本文所述三环化合物在潜在治疗或预防涉及一种或多种突变 IDH 酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• WO2020163544A5
  申请人：——

  公开号：WO2020163544A5

  公开（公告）日：2023-02-14
• NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3226690B1

  公开（公告）日：2020-05-20